Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 25Carcinoma, Non-Small-Cell Lung 6Melanoma 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Neoplasms 2Mesothelioma 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Uveal Melanoma 1Urothelial Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Parotid Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1

Interventions

Sorafenib 5Nivolumab 3lenvatinib 2cabozantinib 2Ipilimumab 2ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1pembrolizumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1durvalumab 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1atezolizumab 1adavosertib 1X-Rays 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Carcinoma, Hepatocellular × pembrolizumab × Clear all
NCT02702414 2024-09-04

KEYNOTE-224

Merck Sharp & Dohme LLC

Phase 2 Completed
156 enrolled 17 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡